Among the 9 surface disinfectants studied, only 2 demonstrated a reduction in viral titer below the limit of detection.

CAV-1 is a key protein in lipid rafts that helps control cellular processes such as growth, survival, and migration.

This action makes inebilizumab the first and only FDA-approved treatment for adults with immunoglobulin G4-related disease (IgG4-RD).

Notably, high levels of high-density lipoprotein cholesterol (HDL-C) were not associated with the risk of dementia following adjustments for triglyceride levels.

Pharmacists can address micronutrient deficiencies, aiding those with type 2 diabetes as they face a higher risk.

Siremadlin is a novel, investigational, second-generation antagonist that binds to MDM2.

Tocilizumab-bavi received FDA approval in September 2023 as the first biosimilar to tocilizumab for the treatment of various adult and pediatric arthritis conditions.

No manufacturing or safety issues were identified, but the FDA stated the new drug application did not demonstrate efficacy in adequate and well-controlled studies.

Generics play a crucial role in mitigating drug shortages by offering a real alternative for 80% of drugs that are becoming increasingly unavailable in Italy.

Through increased utilization of multi-omic data, health care professionals can revolutionize the treatment paradigm of countless diseases.

The predictive tool may reveal the mechanisms underlying treatment resistance in patients with HER+ breast cancer.

Positive results from an interim analysis of the phase 3 ALIGN study bolstered atrasentan towards receiving accelerated approval for patients with immunoglobulin A nephropathy, a rare condition that can cause kidney failure.

Real-time profiling of T-cell activation states in non-CAR T-cells may help guide treatment decisions.

Panelists discuss how optimizing antibody-drug conjugate (ADC) therapy in patients with metastatic breast cancer (mBC) requires interdisciplinary care, including oncologists, pharmacists, and nurses. Adherence barriers such as cost, access, and insurance are addressed via financial and social support.

Panelists discuss how health care professionals use clear, tailored communication to explain antibody-drug conjugate (ADC) risks, benefits, and regimens. They provide education, address concerns, and ensure adherence through counseling and shared decision-making.

Pharmacists play a crucial role in educating patients on proper administration and adherence to GLP-1 treatments.

Nicolas Girard, MD, explains the benefits observed in the MARIPOSA clinical trial among patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated with amivantamab plus lazertinib.

These new phase 3 results indicate the effectiveness of the 2-dose 13-valent pneumococcal conjugate vaccine (PCV13) and 1-dose PCV20 regimens.

The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.

By decade’s end, approval of additional bispecifics is expected for hematological malignancies, solid tumors, and non-oncology conditions such as inflammatory, autoimmune, neurodegenerative and vascular diseases, and ocular disorders and infections.

The registry data showed that cardiac magnetic resonance (CMR) was obtained in more clinically complex patients with recurrent pericarditis.

The Auto-Pure 2400 system combines liquid handling and magnetic cell isolation for efficient latent tuberculosis testing.

Pharmacists performed weekly toxicity and tumor lysis syndrome monitoring.

Similar legislation could also address PBM practices in commercial insurance.

Reducing stigma, improving mental health benefits, and addressing workload concerns all need to happen simultaneously.

Evolving breast cancer risk models and prevention methods are necessary to improve patient outcomes, according to Sagar Sardesai, MD.

Current recommended levels of vitamin B12 might not be sufficient to protect against neurological decline.

John Ostrominski, MD shares insights into the safety and efficacy of finerenone, based on data from the FINEARTS-HF trial.